AAAAAA

   
Results: 1-7 |
Results: 7
In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelicvariant forms of human liver microsomal cytochrome P4502C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics
Authors: Tang, CY Shou, MG Rushmore, TH Mei, Q Sandhu, P Woolf, EJ Rose, MJ Gelmann, A Greenberg, HE De Lepeleire, I Van Hecken, A De Schepper, PJ Ebel, DL Schwartz, JI Rodrigues, AD
Citation: Cy. Tang et al., In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelicvariant forms of human liver microsomal cytochrome P4502C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics, PHARMACOGEN, 11(3), 2001, pp. 223-235
Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients
Authors: Schwartz, JI Agrawal, NGB Wong, PH Bachmann, KA Porras, AG Miller, JL Ebel, DL Sack, MR Holmes, GB Redfern, JS Gertz, BJ
Citation: Ji. Schwartz et al., Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients, J CLIN PHAR, 41(10), 2001, pp. 1120-1130
Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers
Authors: Schwartz, JI De Smet, M Larson, PJ Verbesselt, R Ebel, DL Lins, R Lens, S Porras, AG Gertz, BJ
Citation: Ji. Schwartz et al., Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers, J CLIN PHAR, 41(1), 2001, pp. 107-112
Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers
Authors: Van Hecken, A Schwartz, JI Depre, M De Lepeleire, I Dallob, A Tanaka, W Wynants, K Buntinx, A Arnout, J Wong, PH Ebel, DL Gertz, BJ De Schepper, PJ
Citation: A. Van Hecken et al., Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers, J CLIN PHAR, 40(10), 2000, pp. 1109-1120
The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin
Authors: Schwartz, JI Bugianesi, KJ Ebel, DL De Smet, M Haesen, R Larson, PJ Ko, A Verbesselt, R Hunt, TL Lins, R Lens, S Porras, AG Dieck, J Keymeulen, B Gertz, BJ
Citation: Ji. Schwartz et al., The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin, CLIN PHARM, 68(6), 2000, pp. 626-636
Effect of cyclooxygenase-2 inhibition on renal function in elderly personsreceiving a low-salt diet - A randomized, controlled trial
Authors: Swan, SK Rudy, DW Lasseter, KC Ryan, CF Buechel, KL Lambrecht, LJ Pinto, MB Dilzer, SC Obrda, O Sundblad, KJ Gumbs, CP Ebel, DL Quan, H Larson, PJ Schwartz, JI Musliner, TA Gertz, BJ Brater, DC Yao, SL
Citation: Sk. Swan et al., Effect of cyclooxygenase-2 inhibition on renal function in elderly personsreceiving a low-salt diet - A randomized, controlled trial, ANN INT MED, 133(1), 2000, pp. 1-9
Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans
Authors: Schwartz, JI Chan, CC Mukhopadhyay, S McBride, KJ Jones, TM Adcock, S Moritz, C Hedges, J Grasing, K Dobratz, D Cohen, RA Davidson, MH Bachmann, KA Gertz, BJ
Citation: Ji. Schwartz et al., Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans, CLIN PHARM, 65(6), 1999, pp. 653-660
Risultati: 1-7 |